Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
Hamid Reza Rasekh1, Ali Imani1, Mehran Karimi2, Mina Golestani11Shahid Beheshti University of Medical Sciences, Department of Pharmaceutical Management and Pharmacoeconomics, School of Pharmacy, Tehran, 2University of Shiraz Medical Sciences, Hematology Research Center, Shiraz, IranBackground: In de...
Saved in:
Main Authors: | Rasekh HR (Author), Imani A (Author), Karimi M (Author), Golestani M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2011-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
by: Maria Elisa Mancuso, et al.
Published: (2011) -
Low‐dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor‐titer below 200 BU/mL
by: Zhengping Li, et al.
Published: (2024) -
Successful bleeding control of refractory hemothorax in two hemophilia A patients with high-titer inhibitors
by: Ting-Chih Lin, et al.
Published: (2020) -
GlycoPEGylated recombinant factor IX for hemophilia B in context
by: Santagostino E, et al.
Published: (2018) -
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
by: Mancuso ME, et al.
Published: (2014)